



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid Drug Utilization Review (DUR) Board

Thursday, June 13, 2024, 1:00pm

DMAS -- 600 East Broad Street

Agenda

1. **Call to Order and Introductions** – Rachel Cain, PharmD, Chair
2. **Minutes - Approval of Minutes from the March 14, 2024 meeting**
3. **Physician Administered Drugs (PADs) - Single-Treatment Gene Therapies: Currently Available**
 - **Inpatient**
 - a) Casgevy™ (exagamglogene autotemcel)
 - b) Lyfgenia™ (lovotibeglogene autotemcel)
 - c) Skysona® (elivaldogene autotemcel)
 - d) Zynteglo™ (betibeglogene autotemcel)
 - **Outpatient**
 - a) Elevidys (delandistrogene moxeparvovec)
 - b) Hemgenix® (etranacogene dezaparvovec)
 - c) Luxturna® (voretigene neparvovec-rzyl)
 - d) Roctavian™ (valoctocogene roxaparvovec)
 - e) Vyjuvek® (beremagene geperpavec)
 - f) Zolgensma® (onasemnogene abeparvovec-xioi)
4. **Old Business**
 - a) Utilization of Oral Oncology – Lung Cancer and Other Neoplasm Drugs
5. **DUR Quarterly Newsletter**
6. **MRx Pipeline – Available on WebPortal**
7. **Topics for Discussion**
 - a) Concurrent Use of Opioids and Benzodiazepines
 - b) Concurrent Use of Opioids and Antipsychotics
 - c) Overlaps in Opioids, Benzodiazepines and Antipsychotics
 - d) Naloxone and Buprenorphine Utilization for Members on Opioids



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

8. Reports

- a) ProDUR
- b) RetroDUR
 - i. Recent RetroDUR Activity
 - ii. RetroDUR Criteria Estimates
- c) Utilization Analysis

9. Adjournment

DRAFT